Patents by Inventor Chi-Fang Wu
Chi-Fang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240142671Abstract: An electronic device includes: a first substrate; a second substrate, disposed opposite to the first substrate; an insulating layer, disposed on a surface of the first substrate away from the second substrate; and a metal layer, disposed on a surface of the second substrate away from the first substrate, wherein a width of the insulating layer is different from a width of the metal layer.Type: ApplicationFiled: January 3, 2024Publication date: May 2, 2024Inventors: Chi-Fang WU, Chin-Lung TING, I-Chang LIANG
-
Patent number: 11899166Abstract: An electronic device is disclosed, which includes: a panel, including: a first substrate; a second substrate, disposed opposite to the first substrate; a first protection element, disposed on a surface of the first substrate away from the second substrate; and a first polarizer, disposed on the first protection element.Type: GrantFiled: September 11, 2020Date of Patent: February 13, 2024Assignee: INNOLUX CORPORATIONInventors: Chi-Fang Wu, Chin-Lung Ting, I-Chang Liang
-
Publication number: 20220098568Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: ApplicationFiled: June 10, 2021Publication date: March 31, 2022Inventors: Chi-Fang WU, Darin LEE, Jeffry D. WATKINS, Kristi PIEHL, Kyle CHIANG, Marc THOMAS, Minh-Ha DO, Ying BUECHLER, John D. MENDLEIN
-
Patent number: 11072787Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: GrantFiled: April 7, 2020Date of Patent: July 27, 2021Assignee: aTyr Pharma Inc.Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Publication number: 20200408962Abstract: An electronic device is disclosed, which includes: a panel, including: a first substrate; a second substrate, disposed opposite to the first substrate; a first protection element, disposed on a surface of the first substrate away from the second substrate; and a first polarizer, disposed on the first protection element.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Inventors: Chi-Fang WU, Chin-Lung TING, I-Chang LIANG
-
Patent number: 10809422Abstract: A method for manufacturing an electronic device is disclosed, which includes the following steps: assembling a first mother substrate and a second mother substrate; disposing a first protection element on a surface of the first mother substrate away from the second mother substrate; disposing a first mother polarizer on the first protection element; and processing an assembly of the first mother substrate, the second mother substrate, the first protection element, and the first mother polarizer into a plurality of panels.Type: GrantFiled: September 26, 2018Date of Patent: October 20, 2020Assignee: Innolux CorporationInventors: Chi-Fang Wu, Chin-Lung Ting, I-Chang Liang
-
Publication number: 20200283751Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: ApplicationFiled: April 7, 2020Publication date: September 10, 2020Inventors: Chi-Fang WU, Darin LEE, Jeffry D. WATKINS, Kristi PIEHL, Kyle P. CHIANG, Marc THOMAS, Minh-Ha DO, Ying BUECHLER, John D. MENDLEIN
-
Patent number: 10711260Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: GrantFiled: September 20, 2019Date of Patent: July 14, 2020Assignee: aTyr Pharma, Inc.Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Publication number: 20200149028Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: ApplicationFiled: September 20, 2019Publication date: May 14, 2020Inventors: Chi-Fang WU, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Publication number: 20200096673Abstract: A method for manufacturing an electronic device is disclosed, which includes the following steps: assembling a first mother substrate and a second mother substrate; disposing a first protection element on a surface of the first mother substrate away from the second mother substrate; disposing a first mother polarizer on the first protection element; and processing an assembly of the first mother substrate, the second mother substrate, the first protection element, and the first mother polarizer into a plurality of panels.Type: ApplicationFiled: September 26, 2018Publication date: March 26, 2020Inventors: Chi-Fang WU, Chin-Lung TING, I-Chang LIANG
-
Patent number: 10472618Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: GrantFiled: September 5, 2018Date of Patent: November 12, 2019Assignees: aTyr Pharma, Inc., Pangu Biopharma LimitedInventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Publication number: 20190062720Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: ApplicationFiled: September 5, 2018Publication date: February 28, 2019Inventors: Chi-Fang WU, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Patent number: 10093915Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: GrantFiled: January 25, 2017Date of Patent: October 9, 2018Assignee: aTyr Pharma Inc.Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Patent number: 9822353Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.Type: GrantFiled: December 6, 2012Date of Patent: November 21, 2017Assignee: aTyr Pharma, Inc.Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
-
Patent number: 9816084Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.Type: GrantFiled: December 6, 2012Date of Patent: November 14, 2017Assignee: aTyr Pharma, Inc.Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Kristi Helen Piehl, Jeffrey Greve, John D. Mendlein
-
Publication number: 20170267990Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: ApplicationFiled: January 25, 2017Publication date: September 21, 2017Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
-
Patent number: 9714419Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.Type: GrantFiled: August 8, 2012Date of Patent: July 25, 2017Assignee: aTyr Pharma, Inc.Inventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein
-
Patent number: 9688978Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.Type: GrantFiled: December 27, 2012Date of Patent: June 27, 2017Assignee: aTyr Pharma, Inc.Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
-
Patent number: 9587235Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.Type: GrantFiled: March 14, 2014Date of Patent: March 7, 2017Assignee: aTyr Pharma, Inc.Inventors: Ying Buechler, Kyle Chiang, Minh-Ha Do, Darin Lee, Kristi Piehl, Marc Thomas, Jeffry D. Watkins, Chi-Fang Wu, John D. Mendlein
-
Publication number: 20150159148Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.Type: ApplicationFiled: December 6, 2012Publication date: June 11, 2015Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein